skip to Main Content

Eng Expands on Evolving GI Cancer Landscape

Newsfeed image, light gray text on dark gray background
Recent clinical findings across gastrointestinal (GI) cancers addressed unanswered questions in a number of patient populations, said Cathy Eng, MD.

For example, preliminary results of the PRODIGE 24/CCTG PA.6 trial, which were presented at the 2018 ASCO Annual Meeting, demonstrated a significant improvement in overall survival (OS) for patients with resected pancreatic cancer who received adjuvant therapy with a modified FOLFIRINOX regimen (mFOLFIRINOX) versus gemcitabine. Read more . . .


Back To Top